Amarin Corporation plc

Amarin Corporation plc

Ticker: AMRN

Class Period Start: 12/05/2018

Class Period End: 06/21/2021

Registration Deadline: 12/23/2021

Amarin Corporation plc (“Amarin” or the “Company”) is a biopharmaceutical company specializing in the development of therapeutics for cardiovascular health.

On March 30, 2020, Amarin announced that “the United States District Court for the District of Nevada[] rul[ed] in favor of the generic companies in the company’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise.” On this news, Amarin’s share price fell $9.58, or approximately 70.5%, to close at $4.00 per share on March 31, 2020, thereby injuring investors.

On June 21, 2021, investors learned that the Supreme Court rejected the Company’s bid to revive its Vascepa patents. On this news, Amarin’s share price fell 5.2%, to close at $4.70 per share on June 21, 2021, further injuring investors.

A securities class action has been filed against Amarin on behalf of shareholders that purchased Amarin shares between December 5, 2018 through June 21, 2021.  This case has been filed in the U.S. District Court for the District of New Jersey.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts about Amarin’s business and patent portfolio. Specifically, Defendants made false and misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) once certain of Amarin’s patents were invalidated by the United States District Court for the District of Nevada, there was little to no chance of reversing that ruling; (iii) the Company’s litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing Abbreviated New Drug Application (“ANDA”) litigation posed to the Company’s business and future prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Purchases

Sales

Please Note

Neither the submission to nor the receipt of information by Lowey Dannenberg or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* Indicates a required field.

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.